INSIGHT. From intelligent material design to artificial intelligence. In the future, diagnosis and treatment will use artificial intelligence. There are already several examples in healthcare where artificial intelligence is providing smarter treatments and better diagnostics, and we have only scratched the surface. The market for artificial intelligence in healthcare is expected to exceed USD 100 billion by 2028, representing average annual growth of more than 47% compared to today.
Armed with vast medical knowledge, AI has showcased a remarkable ability to tackle a wide range of clinical questions. Therefore, AI also has enormous potential to contribute to the development of new drugs and match patients with the right treatment. Large pharmaceutical companies like AstraZeneca, as well as innovative technology companies, are now exploring this exciting area.
A perfect example is 82-year-old “Paul” (the patient’s real name was anonymised in the study), who struggled with aggressive blood cancer and seemed to have no options. Paul participated in a clinical trial conducted by the Medical University of Vienna, where AI models were used to select the right drug. Remarkably, two years later, Paul became completely cancer-free, thanks to a drug that had previously been deemed ineffective for his cancer type based on clinical trial results.
Researchers took a small tissue sample from Paul, which contained both healthy cells and cancer cells. The cells were then exposed to various drug combinations, where the researchers observed the cells’ reactions using robot automation and machine learning models. Essentially, the researchers mirrored traditional methods of matching patients with the right drugs, but instead of putting the patient through countless treatments over a long period of time, they tested a range of different treatments at the same time in a laboratory environment. Read more in MIT Technology Review.
This is just one example of all the opportunities that arise with new innovative technology. There is a lot of ongoing research on how processes for matching patients with the right drugs can be streamlined and how new drugs can be brought to market faster and more efficiently. We will continue to follow this exciting area closely!
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information, please visit www.sciety.com and follow us on LinkedIn.
Receive news and invitations from Sciety
Join our newsletter to be the first to know about new investment opportunities and receive invitations to company presentations, seminars, and events.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.